Seattle based Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases

blonca9
Dec 13, 2024
1 min read

Co-founder and CEO Neil McDonnell describes the history of ASK1 and how Seal Rock's program has been optimized to avoid roadblocks that pharma companies experienced in the past. He explains how the company is currently putting it to use in cirrhosis, liver failure (with partner Genfit), and in CNS conditions (along with LRRK2).

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Seattle based Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight